Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Pozycja w akcjach #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Cena akcji
$0.88
Ostatnia synchronizacja: 2026-08-17
Kapitalizacja rynkowa
$10.41M
Zmiana (1 dzień)
-7.26%
Zmiana (1 rok)
-50.56%
Kraj
SG
Handel CytoMed Therapeutics Limited (GDTC)

Kategoria

EPS dla CytoMed Therapeutics Limited (GDTC)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy CytoMed Therapeutics Limited, obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla CytoMed Therapeutics Limited od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów